Digital PCR Can Reliably Determine If Chronic Myeloid Leukemia Patients in Remission Can Successfully Discontinue Drug Treatment

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be discontinued. This transcript that is unique for CML is more sensitive and accurate than the current standard, real-time quantitative PCR (RT-qPCR), for detecting ultralow levels of residual leukemic disease. Results are reported in a novel study 新しいタブ／ウィンドウで開く in The Journal of Molecular Diagnostics 新しいタブ／ウィンドウで開く, published by Elsevier.

Lead investigator Peter E. Westerweel, MD, PhD, Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands, says, "In our research, we show that digital PCR for BCR::ABL reaches a sufficiently high sensitivity in almost all (97%) samples of patients in deep molecular remission. The molecular target was detected in two thirds of patients that were below the limit of detection of standard RT-qPCR technique. Digital PCR was therefore more sensitive and more accurate, allowing a reliable measurement to select CML patients in deep remission eligible for drug treatment discontinuation."

BCR::ABL1 is a specific genetic fusion protein that is characteristic of CML, which is created when two genes, BCR and ABL1, become abnormally joined together. With targeted therapy using tyrosine kinase inhibitors (TKIs), patients with CML may achieve deep molecular responses. Patients who reach this depth of remission can have a normal life expectancy and may qualify for a TKI discontinuation attempt.

In a nationwide prospective multicenter study, samples were collected from Dutch patients with CML for whom a TKI discontinuation attempt was under consideration. From July 2020, a total of 168 samples from 136 patients with CML from 31 medical centers were received until the time of analysis in May 2023.

Commenting on the findings of the study, Dr. Westerweel says, “BCR::ABL1 digital PCR was found to accurately quantify BCR::ABL1 around the level of 0.0023% on the International Scale, which is the clinically relevant prediction cutoff in the context of treatment-free remission. The target sensitivity was set at MR5.0, requiring reliable detection of one transcript in a background of at least 100,000 regular copies. This was achieved in 97% of assessments. Digital PCR was able to detect and quantify the BCR::ABL construct in 68% of samples below the limit of detection of current standard RT-qPCR."

In addition, researchers noted that there was a difference between patients in the fluorescence level of droplets rendered by the digital PCR technique. This was due to a difference in transcript type carried by individual patients. Droplets with higher fluorescence contain the target transcript type and are considered positive while droplets with low fluorescence are considered negative.

Dr. Westerweel explains, "Some patients have a so-called e13a2 transcript type, while others have an e14a2 transcript type. We validated that the assay can be used to identify the transcript type in patients with detectable disease. This additional discovery is very relevant as we have previously shown that the transcript type is a risk factor for molecular relapse after drug discontinuation. Often, the transcript type is not known for patients and cannot be established using standard techniques once patients are in deep remission."

Digital PCR for BCR::ABL in this study used an FDA-approved commercially available assay, which makes general use feasible. This technology may improve the management of CML by enabling more precise monitoring of minimal residual disease and better risk assessment for patients considering treatment-free remission.

Dr. Westerweel concludes, “Digital PCR for BCR::ABL is a valuable and reliable tool to aid clinical decision making in CML.”

Notes for editors

The article is “BCR::ABL1 Deep Molecular Response Quantification and Transcript Type Identification in Chronic Myeloid Leukemia Using a US Food and Drug Administration–Approved Droplet-Based Digital PCR Assay,” by Camille Kockerols, Peter J.M. Valk, Pauline Hogenbirk, Jan J. Cornelissen, and Peter E. Westerweel (https://doi.org/10.1016/j.jmoldx.2024.11.003 新しいタブ／ウィンドウで開く). The article appears in The Journal of Molecular Diagnostics, volume 27, issue 2 (February 2025), published by Elsevier.

The article is openly available at https://www.jmdjournal.org/article/S1525-1578(24)00281-2/fulltext 新しいタブ／ウィンドウで開く.

Full text of this article and additional information are also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected] 新しいタブ／ウィンドウで開く. Journalists wishing to interview the study authors should contact Peter E. Westerweel, MD, PhD, at [email protected] 新しいタブ／ウィンドウで開く.

This study was supported by an Albert Schweitzer Hospital institutional grant and a ZonMw grant 848101002, a governmental funding agency in the Netherlands. The funders of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

About The Journal of Molecular Diagnostics

The Journal of Molecular Diagnostics 新しいタブ／ウィンドウで開く, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.org 新しいタブ／ウィンドウで開く

エルゼビアについて

エルゼビアは情報分析を専門としたグローバル企業として、研究者や医療専門家の方々を支援し、社会にとっての利益最大化に向けて、科学や医療の進展を支えています。これは、信頼できるエビデンスによるコンテンツと高度なAI対応によるデジタル技術に基づく革新的なソリューションにより、知見の集積や重要な意思決定を支援することで実現されています。

エルゼビアは、全世界で9,700人の従業員（うち技術者2,300人以上）を抱え、140年以上にわたって、研究者、図書館員、アカデミックリーダー、資金提供者、政府、研究開発集約型企業、医師、看護師、将来の医療専門家、教育者など研究・医療分野におけるパートナーの重要な活動を支援してきました。エルゼビアが刊行する3,000誌以上の科学ジャーナルと代表的な参考書には、The Lancet 新しいタブ／ウィンドウで開く、Cell Press 新しいタブ／ウィンドウで開くおよびGray’s Anatomyなどをはじめとする、各分野を代表する主要なタイトルが含まれています。 エルゼビア・ファンデーション 新しいタブ／ウィンドウで開くとの活動を通し、私たちがサービスを提供する地域社会と連携して、開発途上国を含む世界中の医学、研究、医療分野における、インクルージョン＆ダイバーシティ（I&D）の改善に努めています。

エルゼビアは、専門家および企業向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Group 新しいタブ／ウィンドウで開くの一事業を担っています。エルゼビアの事業内容、デジタルソリューション、コンテンツなどの詳細については、www.elsevier.comをご覧ください。